Effect of vitamin E on reversibility of renal function following discontinuation of colistin in rats: Histological and biochemical investigations.

This study was carried out to evaluate spontaneous renal regeneration after stopping colistin methanesulfonate (CMS), which induces tubular damage, and the curative effect of Vitamin E (vit E) in rats. Animals were given the following: sterile saline (n = 6), 300,000 IU/kg/ day of CMS (n = 24), or 450,000 IU/kg/day of CMS (n = 24) for seven days. Each CMS group was subdivided into four subgroups (n = 6) and sacrificed as follows: (i) 12 h after stopping CMS, (ii) two weeks after stopping CMS, (iii) two weeks after stopping treatment with vit E, and (iv) two weeks after stopping treatment with olive oil. Subsequently, plasma creatinine (pCr), urine N-acetyl-b-D-glucosaminidase (NAG), renal tissue level of malondialdehyde (MDA), superoxide dismutase (SOD), glutathione reductase (GSH), and renal histology were tested. CMS-induced tubular damage increased the NAG and MDA levels and decreased the SOD and GSH activities. After two weeks of stopping CMS, there was no significant renal recovery. However, treatment with vit E improved tubular regeneration and reduced the biochemical impairments. Two weeks might not be long enough for significant spontaneous renal regeneration. Improvement of renal parameters by vit E could be explained by the reduction of oxidative stress damage. PMID: 29456203 [PubMed - in process]
Source: Saudi Journal of Kidney Diseases and Transplantation - Category: Urology & Nephrology Authors: Tags: Saudi J Kidney Dis Transpl Source Type: research

Related Links:

Conditions:   Pancreas Transplant Rejection;   Kidney Transplant Rejection Intervention:   Diagnostic Test: Allosure Test Sponsors:   Rush University Medical Center;   CareDx Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conclusions: Recipients of experimental HCV D+/R- transplants generally seemed to recognize the risks and benefits of these novel transplants and did not regret participating. Such salutary reported experiences are important in assessing the appropriateness of further research into the feasibility of HCV D+/R- transplants. PMID: 31618112 [PubMed - as supplied by publisher]
Source: AJOB Primary Research - Category: Medical Ethics Tags: AJOB Empir Bioeth Source Type: research
Increased tuberculosis (TB) disease risk has consistently been observed among solid organ transplant recipients [1, 2]. This may result from post-transplant immunosuppressive therapy, although underlying disease processes leading to transplant (including chronic kidney disease) are also associated with increased risk [3]. TB among transplant recipients is associated with increased risk of drug toxicity, drug–drug interactions, graft failure and mortality [4], and can lead to transmission to other vulnerable hospitalised patients. Consequently, global guidelines recommend systematic screening of patients undergoing so...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Original Articles: Research letters Source Type: research
In this study, ASC shee ts were directly transplanted into the kidneys of a DN rat model, and therapeutic consequences were analyzed.Materials and MethodsASCs were isolated from adipose tissues of 7 ‐week‐old EGFP rats, and ASC sheets were prepared using a temperature‐responsive culture dish. DN rat model was established from 5‐week‐old SDT fatty rats. Seven‐week‐old DN rats (n = 21) were assigned to one of the following groups: sham‐operated (n = 6; sham group); ASC suspension (6.0 × 10⁶ cells/mL) administered intravenously (n = 7; ASC i.v. group); and six ASC sheets transplanted directly into the ...
Source: Journal of Diabetes Investigation - Category: Endocrinology Authors: Tags: Original Article Source Type: research
Conditions:   Cytomegalovirus Infection;   Cytomegalovirus Disease Interventions:   Drug: Letermovir tablet;   Drug: Letermovir IV Sponsor:   Merck Sharp & Dohme Corp. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Kidney Transplant Recipient Response to Shingrix Vaccine Intervention:   Biological: Shingrix Sponsor:   University of Colorado, Denver Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Cytomegalovirus Infection;   Cytomegalovirus Disease Interventions:   Drug: Letermovir tablet;   Drug: Letermovir IV Sponsor:   Merck Sharp & Dohme Corp. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Kidney Transplant Recipient Response to Shingrix Vaccine Intervention:   Biological: Shingrix Sponsor:   University of Colorado, Denver Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Cytomegalovirus Infection;   Cytomegalovirus Disease Interventions:   Drug: Letermovir tablet;   Drug: Letermovir IV Sponsor:   Merck Sharp & Dohme Corp. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
CONCLUSION: Immune checkpoint inhibitors are a potential treatment for solid organ transplant patients despite the risk of graft rejection. PMID: 31611026 [PubMed - as supplied by publisher]
Source: Revue des Maladies Respiratoires - Category: Respiratory Medicine Tags: Rev Mal Respir Source Type: research
More News: Kidney Transplant | Kidney Transplantation | Middle East Health | Olive Oil | Saudi Arabia Health | Study | Transplants | Urology & Nephrology | Vitamin E | Vitamins